Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Immunovia AB (publ)    IMMNOV   SE0006091997

IMMUNOVIA AB (PUBL)

(IMMNOV)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Immunovia publ : Invitation to presentation of Immunovia's Full Year Report 2018 on February 14, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:03am EST

Lund (Sweden) - Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 - 6:30 p.m. CET. Immunovia will publish the company's Full Year Report 2018 for the period January - December 2018 on Thursday, February 14, at 5:05 p.m. CET.

Mats Grahn, CEO will present Immunovia and comment on the Full Year Report 2018 followed by a Q&A-session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below:

SE: +46850558352
BE: +3226200547
CH: +41225675632
DE: +4969222220380
DK: +4578150109
FR: +33170750721
NL: +31207219495
NO: +4723500236
UK: +443333009035
US: +16467224956

For questions or interview bookings:
ir@immunovia.com 

There will be an MP3-file available at Immunovia's webpage under Investors/audio-galley (https://immunovia.com/investors/audio-gallery/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

http://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-full-year-report-2018-on-february-14--2019,c2739332

https://mb.cision.com/Main/13121/2739332/989764.pdf

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOVIA AB (PUBL)
02/14IMMUNOVIA PUBL : Full Year report, January-December 2018
AQ
02/14IMMUNOVIA PUBL : to participate in upcoming Investor Conferences in March
AQ
02/12IMMUNOVIA PUBL : Invitation to presentation of Immunovia's Full Year Report 2018..
AQ
02/12IMMUNOVIA PUBL : AB announces appointment of Senior Director of Investor Relatio..
AQ
02/11IMMUNOVIA PUBL : New European sites in Immunovia's PanFAM-1, the largest ever pr..
AQ
2018IMMUNOVIA PUBL : invited to present at Jefferies 2018 London Healthcare Conferen..
AQ
2018IMMUNOVIA PUBL : McGill, Yale and Universities of Pennsylvania and Massachusetts..
AQ
2018IMMUNOVIA PUBL : interim report January-September 2018
AQ
2018IMMUNOVIA PUBL : sponsors primary care educational symposium at Fenway Park in h..
AQ
2018IMMUNOVIA PUBL : Invitation to presentation of Immunovia's interim report Januar..
AQ
More news
Financials (SEK)
Sales 2019 22,6 M
EBIT 2019 -89,8 M
Net income 2019 -88,8 M
Finance 2019 273 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales 2019 104x
Capi. / Sales 2020 -
Capitalization 2 622 M
Chart IMMUNOVIA AB (PUBL)
Duration : Period :
Immunovia AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOVIA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Managers
NameTitle
Mats Peter Egon Grahn Chief Executive Officer
Karl Arne Krister Borrebaeck Chairman
Lotta Blomgren Operations Director
Hans Liljenborg Chief Financial Officer
Lars Bertil Christer Wingren Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOVIA AB (PUBL)9.87%282
SARTORIUS37.50%11 860
MYRIAD GENETICS, INC.8.22%2 305
VAREX IMAGING CORP32.69%1 198
OXFORD IMMUNOTEC GLOBAL PLC32.16%445
SENSUS HEALTHCARE INC1.48%121